Boron Containing Patents (Class 546/13)
-
Patent number: 8664200Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.Type: GrantFiled: September 25, 2009Date of Patent: March 4, 2014Assignee: Millennium Pharmaceuticals, Inc.Inventors: Paul E. Fleming, Jing Li
-
Patent number: 8658795Abstract: Novel pyridinium salts functionalized with boronic acid and methods of making them are disclosed. When combined with a fluorescent dye, the compounds are useful in the detection of polyhydroxyl-substituted organic molecules.Type: GrantFiled: April 25, 2012Date of Patent: February 25, 2014Assignee: Glumetrics, Inc.Inventors: Soya Gamsey, Ritchie A. Wessling
-
Patent number: 8653258Abstract: The present disclosure encompasses compounds and compositions that are useful as specific AI-2 antagonists for the control of bacterial quorum sensing. Although the AI-2 antagonists according to the present disclosure may not have bactericidal effect, their ability to attenuate virulence, drug resistance, and/or biofilm formation have therapeutic benefits. In addition, the AI-2 antagonists of the present disclosure can also be used as tools to probe bacterial AI-2 functions. The present disclosure also encompasses methods for inhibiting or attenuating microbial virulence, biofilm formation, and drug resistance. The methods are suitable for preventing bacteria from accruing and forming extensive biofilms that may be a health or hygiene hazard or a physical issue, such as in the blockage of water or fuel lines.Type: GrantFiled: June 6, 2008Date of Patent: February 18, 2014Assignee: Georgia State University Research Foundation, Inc.Inventors: Binghe Wang, Nanting Ni, Junfeng Wang, Chung-Dar Lu, Han-Ting Chou, Minyong Li, Shilong Zheng, Yunfeng Cheng, Hanjing Peng
-
Patent number: 8648192Abstract: The present invention relates to a compound of formula (I) wherein R1, R2 and n are as defined herein. The invention also relates to processes for making the compounds of formula (I) and methods of using the compounds of formula (I) as reagents in organic synthesis.Type: GrantFiled: May 23, 2011Date of Patent: February 11, 2014Assignee: Boehringer Ingelheim International GmbHInventor: Zhulin Tan
-
Publication number: 20140039193Abstract: Boron-comprising perylene monoimides and a process for producing the boron-comprising perylene monoimides are provided. The boron-comprising perylene monoimides are useful as building blocks for producing perylene monoimide derivatives and monoimide derivatives. The boron-comprising perylene monoimides are also useful for preparing dye-sensitized solar cells.Type: ApplicationFiled: August 5, 2013Publication date: February 6, 2014Applicants: Max-Planck-Gesellschaft zur Foerd. der Wisse. e.V., BASF SEInventors: Henrike Wonneberger, Ingmar Bruder, Robert Send, Glauco Battagliarin, Chen Li, Klaus Muellen
-
Publication number: 20140027734Abstract: Boron-nitrogen polyaromatic compounds having a fused aromatic ring system are provided, where the compounds include a [1,2]azaborino[1,2-a][1,2]azaborine which is optionally fused to one or more aromatic rings or fused aromatic rings; wherein the fused aromatic ring system is substituted by one or more substituents, R, that are not fused to the aromatic ring system, selected from the group consisting of deuterium, halide, alkyl, cycloalkyl, heteroalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carbonyl, carboxylic acids, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, and combinations thereof; and wherein any two adjacent substituents, R, are optionally joined to form one or more non-aromatic rings. Devices, such as organic light emitting devices (OLEDs) that comprise light emitting materials are also provided.Type: ApplicationFiled: March 7, 2013Publication date: January 30, 2014Applicant: Universal Display CorporationInventor: Raymond Kwong
-
Patent number: 8637703Abstract: Methods of synthesizing ammonia borane are provided. The methods comprise reacting at least one amine borane with ammonia such that ammonia borane is produced. Ammonia borane has a chemical formula of NH3.BH3 and provides a good source of storage hydrogen making it useful in a variety of applications including a potential hydrogen source for fuel cells. The methods can further comprise separating the ammonia borane from the other products of the reaction. Exemplary methods can produce ammonia borane having purity greater than about 90 percent. In further examples, the methods can produce ammonia borane having purity greater than about 95 percent or greater than about 99 percent.Type: GrantFiled: June 13, 2011Date of Patent: January 28, 2014Assignee: The Ohio State UniversityInventors: Sheldon Gerald Shore, Xuenian Chen
-
Publication number: 20140023636Abstract: The present invention relates to a compound represented by the formula (I), a salt thereof, an N-oxide form thereof, a solvate thereof, or a prodrug thereof, and a medicament containing the same. The compound represented by the formula (I) has an ability to bind to an S1P receptor (particularly, EDG-1, EDG-6, and/or EDG-8) and is useful for preventing and/or treating for rejection to transplantation, graft-versus-host disease, autoimmune diseases, allergic diseases, neurodegenerating diseases, and the like. wherein all symbols are described in the specification.Type: ApplicationFiled: September 23, 2013Publication date: January 23, 2014Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Hiromu HABASHITA, Haruto KURATA, Shinji NAKADE
-
Publication number: 20140018301Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.Type: ApplicationFiled: November 2, 2012Publication date: January 16, 2014Applicant: MILLENNIUM PHARMACEUTICALS, INC.Inventors: Eric L. Elliott, Abu J. Ferdous, Michael J. Kaufman, Sonja A. Komar, Debra L. Mazaik, Quentin J. McCubbin, Phuong M. Nguyen, Vaithianathan Palaniappan, Raymond D. Skwierczynski, Nobel T. Truong, Csanad M. Varga, Peter N. Zawaneh
-
Publication number: 20140018317Abstract: A compound having a structure of:Type: ApplicationFiled: February 17, 2012Publication date: January 16, 2014Applicant: University of Pittsburgh-Of the Commonwealth System of Higher EducationInventors: Peter Wipf, Marie-Celine Frantz
-
Patent number: 8629125Abstract: The present invention provide compounds, and pharmaceutical compositions thereof, encompassed by the formulae (I), (II) or (III). The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a provided compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH in a patient by administering a therapeutically effective amount of a compound of the formulae (I), (II) or (III), or a pharmaceutical composition thereof, to a patient in need thereof.Type: GrantFiled: October 26, 2012Date of Patent: January 14, 2014Assignee: Infinty Pharmaceuticals, Inc.Inventors: Julian Adams, Mark L. Behnke, Alfredo C. Castro, Catherine A. Evans, Louis Grenier, Michael J. Grogan, Tao Liu, Daniel A. Snyder, Thomas T. Tibbitts
-
Publication number: 20140011998Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.Type: ApplicationFiled: July 3, 2013Publication date: January 9, 2014Applicant: Millennium Pharmaceuticals, Inc.Inventors: Paul E. Fleming, Jing Li
-
Publication number: 20140005399Abstract: The invention provides a polycyclic aromatic compound or a salt thereof having a partial structure represented by the following general formula (I): wherein X, ring A, ring B, ring C, and ring D are as defined in the specification.Type: ApplicationFiled: March 9, 2012Publication date: January 2, 2014Applicant: KYOTO UNIVERSITYInventors: Takuji Hatakeyama, Masaharu Nakamura, Sigma Hashimoto
-
Publication number: 20140005398Abstract: A borate moiety-contained linker and a bio-sensing element containing the same are disclosed. The borate moiety-contained linker can be used to modify a sensing molecule and connect the sensing molecule to a substrate to form the bio-sensing element.Type: ApplicationFiled: January 8, 2013Publication date: January 2, 2014Applicant: NATIONAL CHIAO TUNG UNIVERSITYInventors: Yaw-Kuen LI, Mo-Yuan SHEN, Yu-Ju PIEN
-
Publication number: 20130345172Abstract: Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to 1 cyclic boronic acid ester derivatives and their use as therapeutic agents.Type: ApplicationFiled: July 29, 2013Publication date: December 26, 2013Applicant: Rempex Pharmaceuticals, Inc.Inventors: Gavin Hirst, Raja Reddy, Scott Hecker, Maxim Totrov, David C. Griffith, Olga Rodny, Michael N. Dudley, Serge Boyer
-
Publication number: 20130316943Abstract: Disclosed herein are polybasic bacterial efflux pump inhibitors containing boronic acid functionality and their methods of synthesis, methods of use, and pharmaceutical compositions. Some embodiments include methods of treating or preventing a bacterial infection by co-administering to a subject infected with bacteria or at risk of infection with bacteria the efflux pump inhibitor with another anti-bacterial agent.Type: ApplicationFiled: February 6, 2012Publication date: November 28, 2013Applicant: REMPEX PHARMACEUTICALS, INC.Inventors: Tomasz Glinka, Robert Higuchi, Scott Hecker, Brian Eastman, Olga Rodny
-
Publication number: 20130316978Abstract: Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents.Type: ApplicationFiled: May 21, 2013Publication date: November 28, 2013Inventors: Raja Reddy, Tomasz Glinka, Maxim Totrov, Scott Hecker
-
Publication number: 20130310320Abstract: Disclosed herein is a method for reducing the rate of degradation of proteins in an animal, comprising contacting cells of the animal with certain boronic ester and acid compounds. Also disclosed herein are novel boronic ester and acid compounds, their synthesis and uses.Type: ApplicationFiled: January 11, 2013Publication date: November 21, 2013Applicant: Millennium Pharmaceuticals, Inc.Inventors: Julian Adams, Yu-Ting Ma, Ross L. Stein, Matthew Baevsky, Louis Grenier, Louis Plamondon
-
Patent number: 8586743Abstract: The present disclosure is directed to a reactive ester agent capable of conjugating a reporter molecule to a carrier molecule or solid support. The reactive ester agent has the general formula: wherein the variables are described throughout the application.Type: GrantFiled: January 30, 2008Date of Patent: November 19, 2013Assignee: Life Technologies CorporationInventors: Kyle Gee, Aleksey Rukavishnikov, Diane M. Witczak
-
Patent number: 8586203Abstract: Novel organic compounds comprising ligands containing a boron-nitrogen heterocycle are provided. In particular, the compound is a metal complex comprising a ligand containing an azaborine. The compounds may be used in organic light emitting devices to provide devices having improved photophysical and electronic properties.Type: GrantFiled: May 17, 2010Date of Patent: November 19, 2013Assignee: Universal Display CorporationInventors: Raymond Kwong, Bin Ma, Jui-Yi Tsai, Scott Beers, Ed Barron, Gregg Kottas, Alexey Borisovich Dyatkin
-
Patent number: 8580463Abstract: The present disclosure relates generally to optical data storage media, and more specifically, to holographic storage media. In one embodiment, an optical storage medium includes a polymer matrix having one or more polymer chains. The optical storage medium also includes a reverse saturable absorption (RSA) sensitizer disposed within the polymer matrix that is configured to become excited upon exposure to light having an intensity above an intensity threshold and configured to transfer energy to a reactant. The optical storage medium also includes a diphenyl cyclopropene (DPCP)-derivative reactant disposed within the polymer matrix and capable of undergoing a modification upon receiving an energy transfer from the excited sensitizer that changes a refractive index of the optical medium.Type: GrantFiled: November 17, 2011Date of Patent: November 12, 2013Assignee: General Electric CompanyInventors: Arunkumar Natarajan, Patrick Joseph McCloskey, Eugene Pauling Boden, Kwok Pong Chan, Evgenia Mikhailovna Kim
-
Patent number: 8580464Abstract: The invention relates generally to optical data storage media, and more specifically, to holographic storage media. In one embodiment, an optical storage medium composition includes a polymer matrix. Disposed within the polymer matrix is a reactant capable of undergoing a modification that alters the refractive index of the composition upon receiving an energy transfer from an excited sensitizer. A non-linear sensitizer is also disposed within the polymer matrix, and the sensitizer includes a metal-substituted subphthalocyanine (M-sub-PC) reverse saturable absorber configured to become excited upon exposure to light beyond an intensity threshold at approximately 405 nm and configured to transfer energy to the reactant.Type: GrantFiled: November 17, 2011Date of Patent: November 12, 2013Assignee: General Electric CompanyInventors: Arunkumar Natarajan, Patrick Joseph McCloskey, Kwok Pong Chan, Evgenia Mikhailovna Kim, Robert Edgar Colborn, Eugene Pauling Boden
-
Publication number: 20130289000Abstract: This invention provides, among other things, novel compounds useful for treating inflammatory conditions, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent.Type: ApplicationFiled: June 24, 2013Publication date: October 31, 2013Inventors: Tsutomu Akama, Jacob J. Plattner
-
Patent number: 8551976Abstract: The present invention provides compounds of Formula I along with compositions containing the same and methods of use thereof in treating oxidative stress.Type: GrantFiled: August 1, 2012Date of Patent: October 8, 2013Assignee: Duke UniversityInventors: Katherine J. Franz, Filip Kielar
-
Patent number: 8546564Abstract: Provided herein are compounds of formula (I) or pharmaceutically acceptable salts, solvates or prodrugs thereof, or mixtures thereof, wherein Z1, Z2, X1, X2, X3, R1, R2 R3, m and n are defined herein. Also provided are pharmaceutically acceptable compositions that include a compound of formula I and a pharmaceutically acceptable excipient. Also provided are methods for treating FAAH-mediated disorders comprising administering to a subject in need thereof a therapeutically effective amount of a compound or composition of the present invention.Type: GrantFiled: April 7, 2010Date of Patent: October 1, 2013Assignee: Infinity Pharmaceuticals, Inc.Inventors: Alfredo C. Castro, Michael J. Grogan, Daniel A. Snyder
-
Publication number: 20130252024Abstract: Disclosed are a compound that emits fluorescence, particularly in its solid state, and is suited to provide a color converting material with various improved performance properties over prior art and a light emitter, a color conversion filter, a color conversion device, and a photoelectric device each containing the compound; particularly a Schiff base type compound of formula (I) and a coloring material, a color conversion layer, a light absorbing layer, a color conversion filter, a light absorbing filter, a color-converting light-emitting device, and a photoelectric device each containing the compound. The definition of the symbols in formula (I) is the same as in the specification.Type: ApplicationFiled: May 9, 2013Publication date: September 26, 2013Applicant: ADEKA CORPORATIONInventors: Mitsuhiro OKADA, Koichi SHIGENO
-
Patent number: 8541581Abstract: Provided herein are compounds of formula (I): or pharmaceutically acceptable salts, solvates or prodrugs thereof or mixtures thereof, wherein Z1, Z2, X1, X2, X3, R1, R2, R3, R4, m and n are defined herein. Also provided are pharmaceutically acceptable compositions that include a compound of formula I and a pharmaceutically acceptable excipient. Also provided are methods for treating an FAAH-mediated disorder comprising administering to a subject in need thereof a therapeutically effective amount of a compound or composition of the present invention.Type: GrantFiled: April 7, 2010Date of Patent: September 24, 2013Assignee: Infinity Pharmaceuticals, Inc.Inventors: Alfredo C. Castro, Catherine A. Evans, Louis Grenier, Michael J. Grogan
-
Publication number: 20130225524Abstract: The invention is directed to substituted quinoline derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2, R3, R4, and R5 are defined herein. The compounds of the invention are inhibitors of lactate dehydrogenase A and can be useful in the treatment of cancer and diseases associated with tumor cell metabolism, such as cancer, and more specifically cancers of the breast, colon, prostate and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting lactate dehydrogenase A activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.Type: ApplicationFiled: November 3, 2011Publication date: August 29, 2013Inventors: Deping Chai, Mariela Colon, Christopher Dodson, Kevin J. Duffy, Antony Nicholas Shaw
-
Patent number: 8513218Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.Type: GrantFiled: March 30, 2011Date of Patent: August 20, 2013Assignee: Millennium Pharmaceuticals, Inc.Inventors: Paul E. Fleming, Jing Li
-
Publication number: 20130210158Abstract: Quaternary nitrogen heterocyclic boronic acid-containing compounds are described, which are sensitive to glucose and fructose, as well as a variety of other physiologically important analytes, such as aqueous chloride and iodide, and a method of using the compounds. Also disclosed is a contact lens doped with the quaternary nitrogen heterocyclic boronic acid-containing compound, and a method of using the doped contact lens to measure the concentration of analyte in tears under physiological conditions.Type: ApplicationFiled: December 24, 2012Publication date: August 15, 2013Inventors: CHRIS D. GEDDES, RAMACHANDRAM BADUGU, JOSEPH R. LAKOWICZ
-
Publication number: 20130210053Abstract: The invention provides luminescent solid-state compositions comprising difluoroboron beta-diketonates wherein the compositions can exhibit mechanochromic luminescence. The mechanochromic effect on the luminescence can be reversible, such as thermally reversible. Various solid-state forms of the invention can have emission spectra that differ from the properties of the respective difluoroboron beta-diketonate in solution. The mechanochromic effect can be stimulated by pressure such as hand-writing, and can be reversed over a period of minutes to hours at room temperature. The invention also provides methods of making and methods of using the solid-state compositions, such as for sensors and for information displays for use in biological sensing, and in art, design, and consumer products.Type: ApplicationFiled: December 1, 2010Publication date: August 15, 2013Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATIONInventors: Cassandra L. Fraser, Guoqing Zhang
-
Patent number: 8507680Abstract: The present invention provides a production process of a heteroaryl mono- or diboron compound comprising an aromatic heterocyclic compound and a boron compound in the form of bis(pinacolate)diboron or pinacolate diborane in the presence of a iridium-containing catalyst and a ligand such as a bipyridyl ligand. The reaction is conducted in a single step under mild conditions and allows for changing the charged ratios of the raw materials.Type: GrantFiled: February 9, 2012Date of Patent: August 13, 2013Assignee: Mitsubishi Rayon Co., Ltd.Inventors: Norio Miyaura, Tatsuo Ishiyama
-
Publication number: 20130203985Abstract: The present invention relates to a compound of formula (I) wherein R1, R2 and n are as defined herein. The invention also relates to processes for making the compounds of formula (I) and methods of using the compounds of formula (I) as reagents in organic synthesis.Type: ApplicationFiled: May 23, 2011Publication date: August 8, 2013Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventor: Zhulin Tan
-
Publication number: 20130190496Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.Type: ApplicationFiled: January 11, 2013Publication date: July 25, 2013Inventor: OSI Pharmaceuticals, LLC
-
Publication number: 20130184461Abstract: Mechanosynthesis trajectories are described which are approximately coaxial, and are shown to be useful in a wide range of mechanosynthesis reactions regardless of the nature of the tip or the feedstock being transferred.Type: ApplicationFiled: February 28, 2013Publication date: July 18, 2013Inventors: Robert A. Freitas, JR., Ralph C. Merkle
-
Publication number: 20130178627Abstract: Methods and systems for building three-dimensional workpieces are described using a plurality of mechanosynthetic reactions. These methods may employ engineered reliability in reactions and process conditions and may use simulated or otherwise vetted reaction sequences, to allow workpieces requiring many reactions to be built with acceptable reliability. These many reactions may be the repetition of one or a small number of reactions, or many diverse reactions, or a combination thereof.Type: ApplicationFiled: February 28, 2013Publication date: July 11, 2013Inventors: Robert A. Freitas, JR., Ralph C. Merkle
-
Publication number: 20130178626Abstract: Processes are described for manufacturing atomically-precise tips using one or more tips in one or more mechanosynthetic reactions to create one or more atomically-precise tips. The processes may employ a variety of feedstock, binding any of a wide range of atoms to a workpiece to build the one or more atomically-precise tips. The processes result in atomically-precise mechanosynthesis tips with a wide variety of possible tip structures using a wide range of feedstock binding elements. Characteristics of such tips that may be used when designing new embodiments are also described.Type: ApplicationFiled: February 28, 2013Publication date: July 11, 2013Inventors: Robert A. Freitas, JR., Ralph C. Merkle
-
Publication number: 20130178472Abstract: The invention relates to pyridine-pyridinone derivatives general formula (I): in which R1, R2, R3, R4, n, n?, V, W, Y, Z, Ar are as defined in the description, and to their methods of preparation and their therapeutic applications.Type: ApplicationFiled: July 2, 2012Publication date: July 11, 2013Applicant: SANOFIInventors: Patrice BELLEVERGUE, Patrick GRAILHE, Gary MCCORT, Stephen O'CONNOR, Olivier DUCLOS
-
Publication number: 20130165390Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.Type: ApplicationFiled: November 2, 2012Publication date: June 27, 2013Applicant: MILLENNIUM PHARMACEUTICALS, INC.Inventor: Millennium Pharmaceuticals, Inc.
-
Patent number: 8470803Abstract: This invention provides, among other things, novel compounds useful for treating inflammatory conditions, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent.Type: GrantFiled: September 10, 2009Date of Patent: June 25, 2013Assignee: Anacor Pharmaceuticals, Inc.Inventors: Tsutomu Akama, Jacob J. Plattner
-
Patent number: 8466286Abstract: Small Molecule Metabolite Reporters (SMMRs) for use as in vivo glucose biosensors, sensor compositions, and methods of use, are described. The SMMRs include boronic acid-containing xanthene, coumarin, carbostyril and phenalene-based small molecules which are used for monitoring glucose in vivo, advantageously on the skin.Type: GrantFiled: August 22, 2011Date of Patent: June 18, 2013Assignee: Cercacor Laboratories, Inc.Inventors: Emile M. Bellott, Dongsheng Bu, James J. Childs, Christopher Lambert, Hubert A. Nienaber, Shirley J. Shi, Zhaolin Wang, Jerome J. Workman, Alex R. Zelenchuk
-
Publication number: 20130150326Abstract: Described herein are compounds that are inhibitors of autotaxin. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such inhibitors, alone and in combination with other compounds, for treating autotaxin-dependent or autotaxin-mediated conditions or diseases.Type: ApplicationFiled: August 19, 2011Publication date: June 13, 2013Applicant: Amira Pharmaceuticals, Inc.Inventors: Jeffrey Roger Roppe, Timothy Andrew Parr, Nicholas Simon Stock, Deborah Volkots, John Howard Hutchinson
-
Patent number: 8461135Abstract: Compounds and methods of treating anti-inflammatory conditions are disclosed.Type: GrantFiled: September 19, 2011Date of Patent: June 11, 2013Assignee: Anacor Pharmaceuticals, Inc.Inventors: Tsutomu Akama, Yong-Kang Zhang, Charles Z. Ding, Jacob J. Plattner, Kirk R. Maples, Yvonne Freund, Virginia Sanders, Yi Xia, Stephen J. Baker, James A. Nieman, Xiaosong Lu, Marcelo Sales, Rashmi Sharma, Rajeshwar Singh, Robert T. Jacobs, Daitao Chen, Michael Richard Kevin Alley
-
Patent number: 8461336Abstract: This invention provides, among other things, novel compounds useful for treating inflammatory conditions, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent.Type: GrantFiled: September 2, 2009Date of Patent: June 11, 2013Assignee: Anacor Pharmaceuticals, Inc.Inventors: Yasheen Zhou, Yong Kang Zhang, Tsutomu Akama, Kurt Jarnagin
-
Publication number: 20130136794Abstract: Heteroaryl(alkyl)dithiocarbamate compounds represented by general formula (I) or their pharmaceutically acceptable salts, their preparing methods, and their uses for preparing antitumor medicines are disclosed, wherein each said substituent is defined as in the description. The compounds are new tyrosine kinase inhibitors useful as an anti-tumor agents, preferably useful in the preparation of medicines for treating breast cancer, liver cancer, non-small cell lung cancer, gastric cancer, colon cancer, leukaemia or nasal cancer.Type: ApplicationFiled: April 21, 2011Publication date: May 30, 2013Applicant: PEKING UNIVERSITYInventors: Runtao Li, Zemei Ge, Jingrong Cui, Xingyl Sun, Zhongqing Wang, Xu Yan
-
Publication number: 20130131017Abstract: This invention provides novel compounds, methods of using the compounds, and pharmaceutical compositions containing the compounds.Type: ApplicationFiled: November 16, 2012Publication date: May 23, 2013Applicants: Anacor Pharmaceuticals, Inc., Eli Lilly and CompanyInventors: Eli Lilly and Company, Anacor Pharmaceuticals, Inc.
-
Patent number: 8436173Abstract: The present invention provides novel boron compounds which are useful, depending on their characteristics, as light-emitting materials, electron-transport materials, electron-injection materials, hole-blocking materials, or organic semiconductor materials, and which have new molecular structures quite different from those of the heretofore known boron compounds; their production processes; and functional electronic devices using the same. The novel boron compounds are, for example, those of the following formula (1): These boron compounds can be produced by, for example, reacting boron compounds of the following formula (4): with compounds of the following formula (5): in the presence of a catalyst containing at least one metal element selected from the group consisting of palladium, platinum, and nickel. These boron compounds are used for the functional electronic devices.Type: GrantFiled: December 4, 2008Date of Patent: May 7, 2013Assignees: Kyoto University, Nippon Shokubai Co., Ltd.Inventors: Masahiro Murakami, Naoki Ishida, Mizuna Narumi, Yoichi Arimoto, Munehiro Hasegawa, Tomoya Arai, Tsuyoshi Goya
-
Publication number: 20130102782Abstract: The present invention relates to processes and intermediates for the preparation of compounds useful as inhibitors of Janus kinases (JAK).Type: ApplicationFiled: July 3, 2012Publication date: April 25, 2013Applicant: Vertex Pharmaceuticals IncorporatedInventors: Gerald J. Tanoury, Young Chun Jung, Derek Magdziak, Adam Looker, Billie J. Kline, Václav Jurcík, Beatriz Dominguez Olmo
-
Publication number: 20130096085Abstract: Prochelator compounds of Formula (I) or Formula (II) are described, along with methods of using the same and pharmaceutical formulations or compositions containing the same.Type: ApplicationFiled: July 22, 2010Publication date: April 18, 2013Inventors: Katherine J. Franz, Marina G. D, Leed
-
Publication number: 20130090309Abstract: The invention provides certain amino-pyridine-containing compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and n are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.Type: ApplicationFiled: April 30, 2012Publication date: April 11, 2013Inventors: Eric Thomas Romeo, Michelle R. Machacek, Benjamin Wesley Trotter, Thomas Allen Miller, Brian Michael Andresen, Neville John Anthony, Brandon M. Taoka, Yuan Liu